Clinical Trial

WaKING: Wnt and checKpoint INhibition in Gastric Cancer

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a multicentre open-label non-randomised, Single Stage Ahern Design (with a 3+3 design for the safety run-in) phase II clinical trial of DKN-01 plus atezolizumab in patients with advanced unresectable or metastatic OGA who have progressed following chemotherapy.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2019-11-15; most recent amendment 2025-04-02.
Status change: Recruiting → Active, Not Recruiting 2024-08-01
Status change: Not Yet Recruiting → Recruiting 2020-02-19
Trial Details
NCT Number NCT04166721
Lead Sponsor Royal Marsden NHS Foundation Trust
Conditions Metastatic Esophageal Cancer, Metastatic Gastric Cancer
Enrollment 52 participants
Start Date 2020-02-11
Primary Completion 2025-03-30 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-04-06